Cargando…
Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response
Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for the treatment of active relapsing-remitting multiple sclerosis (MS). Alemtuzumab induces a rapid and prolonged depletion of lymphocytes from the circulation, which results in a profound immuno-suppression status followed by an i...
Autores principales: | Rotondi, Mario, Molteni, Martina, Leporati, Paola, Capelli, Valentina, Marinò, Michele, Chiovato, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626941/ https://www.ncbi.nlm.nih.gov/pubmed/29033895 http://dx.doi.org/10.3389/fendo.2017.00254 |
Ejemplares similares
-
Alemtuzumab-Induced Autoimmune Thyroid Dysfunction
por: Ragavan, Sharanniyan, et al.
Publicado: (2022) -
Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?
por: Rotondi, Mario, et al.
Publicado: (2018) -
Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis
por: Iadarola, Carmine, et al.
Publicado: (2019) -
Editorial: TSH Receptor and Autoimmunity
por: Davies, Terry F., et al.
Publicado: (2019) -
Thyroid Disrupting Effects of Old and New Generation PFAS
por: Coperchini, Francesca, et al.
Publicado: (2021)